Antibody Responses to Schistosoma mansoni Schistosomula Antigens

Authors Organisations
  • Moses Egesa(Author)
    Uganda Virus Research Institute
  • Lawrence Lubyayi(Author)
    Uganda Virus Research Institute
  • Frances M. Jones(Author)
    University of Cambridge
  • Angela van Diepen(Author)
    Leiden University Medical Center
  • Iain Chalmers(Author)
  • Edridah M. Tukahebwa(Author)
    Vector Control Division, Ministry of Heath, Uganda
  • Bernard S. Bagaya(Author)
    Makerere University College of Health Sciences
  • Cornelis H. Hokke(Author)
    Leiden University Medical Center
  • Karl Hoffmann(Author)
  • David W. Dunne(Author)
    University of Cambridge
  • Alison M. Elliot(Author)
    London School of Hygiene and Tropical Medicine
    Uganda Virus Research Institute
  • Maria Yazdanbakhsh(Author)
    Leiden University Medical Center
  • Shona Wilson(Author)
    University of Cambridge
  • Stephen Cose(Author)
    London School of Hygiene and Tropical Medicine
    Uganda Virus Research Institute
Type Article
Original languageEnglish
Article numbere12591
JournalParasite Immunology
Issue number12
Early online date21 Sep 2018
Publication statusPublished - 14 Oct 2018
Show download statistics
View graph of relations
Citation formats


While antigens from Schistosoma schistosomula have been suggested as potential vaccine candidates, the association between antibody responses to schistosomula antigens and infection intensity at reinfection is not well-known. Schistosoma mansoni infected individuals were recruited from a schistosomiasis endemic area in Uganda (n=372), treated with 40mg/kg praziquantel (PZQ) and followed up at five weeks and at one-year post-treatment. Pre-treatment and five-week post-treatment immunoglobulin (Ig) E, IgG1 and IgG4 levels against recombinant schistosomula antigens rSmKK7, rSmLy6A, rSmLy6B and rSmTSP7 were measured using ELISA. Factors associated with detectable pre-treatment or post-treatment antibody response against the schistosomula antigens and the association between five-week antibody responses and one-year post-treatment reinfection intensity among antibody responders were examined. Being male was associated with higher pre-treatment IgG1 to rSmKK7, rSmLy6a and AWA. Five-week post-treatment antibody responses against schistosomula antigens were not associated with one-year post-treatment reinfection intensity among antibody responders' antibody levels against rSmKK7, rSmLy6B and rSmTSP7 dropped, but increased against rSmLy6A, AWA and SEA at five weeks post-treatment among antibody responders. S. mansoni infected individuals exhibit detectable antibody responses to schistosomula antigens that are affected by treatment. These findings indicate that schistosomula antigens induce highly varied antibody responses and could have implications for vaccine development.


  • Schistosoma mansoni, IgE, antibody responder, reinfection, schistosomula antigens